Related Experiment Video
Updated: Jun 5, 2025
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire
Sui Hsien Wong1, Rebhi Abuzaitoun1, Wayne T Cornblath1
1From the Department of Neuro-Ophthalmology (S.H.W.), Moorfields Eye Hospital NHS Foundation Trust; Departments of Ophthalmology and Neurology (S.H.W.), Guy's and St Thomas' NHS Foundation Trust; Department of Ophthalmology (S.H.W.), Faculty of Life Sciences & Medicine, King's College London; Department of Clinical and Movement Neuroscience (S.H.W.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Ophthalmology and Visual Sciences (R.A., W.T.C., T.D., J.R.E., C.A.A., L.B.D.L.), Kellogg Eye Center, University of Michigan, Ann Arbor; Departments of Ophthalmology, Neurology, and Neurosurgery (E.R.E., S.K.), Mayo Clinic, FL; Survey Research Center (J.R.E.), Institute for Social Research, University of Michigan, Ann Arbor; and Division of Neurology (C.B.-T.), Department of Medicine, University Health Network and University of Toronto, Ontario, Canada.
The OMG Rating Scale Questionnaire (OMGRate-q) is a validated tool for assessing ocular myasthenia gravis (OMG) symptoms like ptosis and diplopia. This patient-reported outcome measure supports patient-centered care and research in OMG.
Area of Science:
- Ophthalmology
- Neurology
- Patient-Reported Outcomes
Background:
- Ocular myasthenia gravis (OMG) presents with debilitating ptosis and diplopia.
- A validated, disease-specific patient-reported outcome measure (PROM) for OMG was lacking.
- This study aimed to validate the novel OMG Rating Scale Questionnaire (OMGRate-q) for visual functioning.
Purpose of the Study:
- To validate the OMGRate-q as a reliable and disease-specific PROM for ocular myasthenia gravis.
- To assess the instrument's ability to measure visual functioning in OMG patients.
- To support patient-centered care and research in OMG.
Main Methods:
- Prospective validation study of the 10-item OMGRate-q in 134 adult OMG patients across 3 medical centers.
- Exploratory factor analysis and Andrich rating scale modeling were used for item analysis.
- Test-retest reliability and correlation with existing myasthenia gravis PROMs were assessed.
Main Results:
- The OMGRate-q demonstrated good psychometric properties, with high test-retest reliability for the diplopia subscale (ICC=0.95) and good reliability for the ptosis item (κ=0.56).
- Scores correlated moderately to highly with established measures like the Myasthenia Gravis Quality of Life 15 and Myasthenia Gravis Impairment Index.
- The questionnaire was well-accepted by participants and completed quickly.
Conclusions:
- The OMGRate-q is a valid and reliable disease-specific PROM for ocular myasthenia gravis.
- The OMGRate-q can facilitate patient-centered research and care for OMG.
- Further research is needed to assess OMGRate-q responsiveness and refine ptosis measurement within the scale.
More Related Videos
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...